Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nortriptyline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 7/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 5/20 | 1.00 |
| ▸ | HRH1 | P35367 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 6/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | HTR2B | P41595 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 5/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | DRD2 | P14416 | 5/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 5/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 5/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 5/20 | 1.00 |
| ▸ | HTR2A | P28223 | 5/20 | 1.00 |
| ▸ | HTR2C | P28335 | 5/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 5/20 | 1.00 |
| ▸ | DRD3 | P35462 | 5/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nortriptyline SCHEMBL1286980 | 1.00 | SLC6A2 (1.00) | SLC6A2HRH1LMNACYP3A4CYP1A2 | |
| Nortriptyline SCHEMBL34527 | 1.00 | SLC6A2 (1.00) | SLC6A2HRH1LMNACYP3A4CYP1A2 | |
| Nortriptyline SCHEMBL41329 | 0.98 | CYP3A4 (1.00) | SLC6A2HRH1LMNACYP3A4CYP1A2 | |
| Nortriptyline SCHEMBL29751879 | 0.98 | CYP3A4 (1.00) | SLC6A2HRH1LMNACYP3A4CYP1A2 | |
| Nortriptyline SCHEMBL7158809 | 0.98 | SLC6A2 (0.97) | SLC6A2HRH1LMNACYP3A4CYP1A2 | |
| Nortriptyline SCHEMBL7092935 | 0.97 | LMNA (0.94) | SLC6A2HRH1LMNACYP3A4CYP1A2 | |
| Nortriptyline SCHEMBL2244623 | 0.97 | SLC6A2 (0.94) | SLC6A2HRH1LMNACYP3A4CYP1A2 | |
| Amitriptyline SCHEMBL3897883 | 0.90 | SLC6A2 (0.81) | SLC6A2HRH1LMNACYP3A4CYP1A2 | |
| SCHEMBL21859431 | 0.89 | LMNA (0.78) | SLC6A2HRH1LMNACYP3A4CYP1A2 | |
| SCHEMBL22147029 | 0.89 | LMNA (0.78) | SLC6A2HRH1LMNACYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3714986-B1 | ROD AND ASSEMBLY FOR SUCTION OF LIQUID PAINT AND METHOD FOR MANUFACTURING SUCH A ROD | EXEL IND (FR) | 2026-03-11 | — | — | EP | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| EP-3986401-B1 | THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-1-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | STEALTH BIOTHERAPEUTICS INC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-3567243-B1 | WIND TURBINE BLADE LEADING EDGE PROTECTION | GENERAL ELECTRIC RENOVABLES ESPANA SL (ES) | 2026-01-28 | — | — | EP | claimed |
| EP-3931189-B1 | AZEPINO-INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | UNIV CALIFORNIA (US) | 2025-12-24 | — | — | EP | claimed |
| EP-4212424-B1 | MECHANICAL CONNECTION DEVICE DESIGNED FOR THE DETACHABLE MECHANICAL CONNECTION OF THE FREE ENDS OF TWO OFFSHORE LINES | NOV BLM (FR) | 2025-12-17 | — | — | EP | claimed |
| US-12396988-B2 | Methods of using muscarinic antagonists in the treatment of depression | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-08-26 | — | — | US | claimed |
| EP-4363142-B1 | METHOD OF DRILLING STRUCTURE PIECES TO BE ASSEMBLED AND DRILLING TOOL | LATECOERE (FR) | 2025-08-06 | — | — | EP | claimed |
| WO-2025083356-A1 | VENTILATION CIRCUIT FOR TURBINE ENGINE | SAFRAN AIRCRAFT ENGINES (FR) | 2025-04-24 | — | — | WO | claimed |
| EP-3180349-B1 | LYMPH DIRECTING PRODRUGS AND THERAPEUTIC USES THEREOF | UNIV MONASH (AU) | 2025-03-12 | — | — | EP | claimed |
| WO-2023274736-A1 | METHOD FOR DRILLING STRUCTURAL PARTS TO BE ASSEMBLED AND DRILLING TOOL | LATECOERE (FR) | 2023-01-05 | — | — | WO | claimed |
| EP-3803063-B1 | PIPE ASSEMBLY COMPRISING AN OUTLET OF A HOT-GAS PIPE OF AN AIRCRAFT ENGINE PASSING THROUGH AN ENGINE WALL | SAFRAN AIRCRAFT ENGINES (FR) | 2022-12-21 | — | — | EP | claimed |
| EP-3891505-B1 | A METHOD FOR MEASURING A CONCENTRATION OF A BIOMARKER/ANALYTE IN BLOOD FROM MAMMALS | REDHOTDIAGNOSTICS AB (SE) | 2022-11-30 | — | — | EP | claimed |
| US-11512353-B2 | Method to predict response to neuropsychiatric drugs using variation in the serotonin 7 receptor (HTR7) gene | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-11-29 | — | — | US | claimed |
| EP-3406453-B1 | DEVICE FOR PRINTING AND CORRESPONDING METHOD | TARKETT GDL SA (LU) | 2022-09-07 | — | — | EP | claimed |
| EP-3380222-B1 | MODULAR CATALYST MONOLITHS | BASF SE (DE) | 2022-08-03 | — | — | EP | claimed |
| US-20220187315-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSING DEPRESSION | DUKE UNIVERSITY | 2022-06-16 | — | — | US | claimed |
| US-20220152005-A1 | METHODS OF USING MUSCARINIC ANTAGONISTS IN THE TREATMENT OF DEPRESSION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-05-19 | — | — | US | claimed |
| EP-3454853-B1 | TREATMENT OF ALCOHOLISM AND DEPRESSION USING IBUDILAST | MEDICINOVA INC (US) | 2022-05-18 | — | — | EP | claimed |
| EP-3803095-B1 | AN AIR SUPPLY ARRANGEMENT FOR SUPPLYING AIR TO AN INTERNAL COMBUSTION ENGINE | VOLVO TRUCK CORP (SE) | 2022-03-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220152005-A1 | METHODS OF USING MUSCARINIC ANTAGONISTS IN THE TREATMENT OF DEPRESSION | CHRM5, CHRM3, CHRM2 | SLC6A2 187/4885SLC6A4 165/4885HRH1 148/4885 |
| US-12396988-B2 | Methods of using muscarinic antagonists in the treatment of depression | CHRM5, CHRM3, CHRM2 | SLC6A2 187/4885SLC6A4 165/4885HRH1 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.